Literature DB >> 6853404

The pharmacokinetics of temocillin in patients with normal and impaired renal function.

J Boelaert, R Daneels, M Schurgers, A M Lambert, H W Van Landuyt, G Mellows, J Wolf, A J Swaisland.   

Abstract

The pharmacokinetics of temocillin was studied in 16 subjects with varying degrees of renal functional impairment. The subjects were divided into three groups, depending on their creatinine clearance: Group A greater than 70 ml/min/1.73 m2; Group B 20-70ml/min/1.73 m2 and Group C less than 20 ml/min/1.72 m2. Following intravenous administration the total serum clearance of temocillin was reduced in patients with renal insufficiency. The distribution of temocillin into the tissues was not affected by renal dysfunction, apparent distribution volumes being 15.11, 16.01 and 13.81 in Groups A, B and C respectively. The change in clearance was reflected in an increased area under the serum concentration versus time curve from 418 mg h/l in Group A to 1301 mg h/l and 1553 mg h/l in Groups B and C respectively. The beta elimination half-life was also prolonged from 3.5 h in Group A 12.7 h in Group B and 17.5 h in Group C. The urinary excretion of temocillin was both delayed and reduced according to the extent of kidney damage. The reduction in temocillin clearance was proportional to the extent of reduction from normal of the clearance of creatinine. This relationship has been used to suggest dosage schedules for temocillin in patients with renal insufficiency.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6853404     DOI: 10.1093/jac/11.4.349

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

Review 1.  Pharmacokinetics and Pharmacodynamics of Temocillin.

Authors:  Kevin Alexandre; Bruno Fantin
Journal:  Clin Pharmacokinet       Date:  2018-03       Impact factor: 6.447

Review 2.  Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes.

Authors:  David van Duin; Keith S Kaye; Elizabeth A Neuner; Robert A Bonomo
Journal:  Diagn Microbiol Infect Dis       Date:  2013-01-03       Impact factor: 2.803

3.  Temocillin in the treatment of gram-negative septicaemia.

Authors:  H W Van Landuyt; A Lambert; A Van Couter; J Boelaert
Journal:  Drugs       Date:  1985       Impact factor: 9.546

4.  Effect of temocillin and moxalactam on platelet responsiveness and bleeding time in normal volunteers.

Authors:  B Nunn; A Baird; P D Chamberlain
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

5.  Temocillin. In vitro activity compared with other antibiotics.

Authors:  J Martinez-Beltran; E Loza; A Gomez-Alferez; J Romero-Vivas; E Bouza
Journal:  Drugs       Date:  1985       Impact factor: 9.546

6.  In vitro activity of temocillin against clinical isolates.

Authors:  H W Van Landuyt; J Boelaert; P Piot; L Verbist
Journal:  Drugs       Date:  1985       Impact factor: 9.546

7.  Effect of renal function and dialysis on temocillin pharmacokinetics.

Authors:  J Boelaert; R Daneels; M Schurgers; G Mellows; A J Swaisland; A M Lambert; H W Van Landuyt
Journal:  Drugs       Date:  1985       Impact factor: 9.546

8.  Pharmacokinetics and tissue penetration of temocillin.

Authors:  M R Lockley; R M Brown; R Wise
Journal:  Drugs       Date:  1985       Impact factor: 9.546

9.  Performance of a diffusional clearance model for beta-lactam antimicrobial agents as influenced by extravascular protein binding and interstitial fluid kinetics.

Authors:  J C Fleishaker; P J McNamara
Journal:  Antimicrob Agents Chemother       Date:  1985-09       Impact factor: 5.191

10.  Anti-infective Medicines Use in Children and Neonates With Pre-existing Kidney Dysfunction: A Systematic Review.

Authors:  Chiara Minotti; Elisa Barbieri; Denis Doni; Cristina Impieri; Carlo Giaquinto; Daniele Donà
Journal:  Front Pediatr       Date:  2022-04-26       Impact factor: 3.569

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.